SD explained that the main barriers discussed were about how this pathway has not come from a governmental process but from a need expressed by patients, partly because QFIT was rolled out and there’s a lack of access to calprotectin, as well as that GI symptoms can present in a number of ways and there’s several different conditions it could be.